Back

A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 7 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rohit Mathur

dr.sn medical college, Jodhpur (India)

7 More presentations in this session

Presentation thumbnail
Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
Associate Professor P. Ameri (Genova, IT)
Abstract Slides Video
Presentation thumbnail
Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Diuresis efficacy in ambulatory congested heart failure patients: Intra -patient comparison of three diuretic regimens (DEA-HF)
Doctor A. Abbo (Haifa, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension
thumbnail
Congress Presentation
A meta-analysis of the effects of sacubitril-valsartan on surrogate markers of systemic right ventricular dysfunction in congenital heart disease
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources